This trial is being done to see if lenvatinib is safe and effective in treating patients with a type of thyroid cancer called differentiated thyroid cancer (DTC) that has spread outside of the thyroid gland.
1 Primary · 6 Secondary · Reporting Duration: Up to 18 months
30 Total Participants · 1 Treatment Group
Primary Treatment: LENVATINIB · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: